You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of recombinant VSV vaccines for emerging bunyaviruses

    SBC: Advac Therapeutic LLC            Topic: NIAID

    PROJECT SUMMARY/ABSTRACT Emerging viral infections remain a global threat to human health. Bunyaviruses are the largest order of RNA viruses that includes many clinically relevant human pathogens such as Lassa, Rift Valley Fever and various hantaviruses which cause viral hemorrhagic fever (VHF). SFTSV, or Severe fever with thrombocytopenia syndrome virus, is an emerging tick-borne bunyavirus that ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Novel multi-sensing seat cover system for prevention of sitting-related pressure injuries in individuals with Alzheimer's disease or related dementias

    SBC: Adapt Design Works, LLC            Topic: NIA

    ABSTRACT The long-term objective of this project is to create a sensor-based monitoring technology for use by caregivers, clinicians, and individuals living with Alzheimer’s disease or Alzheimer’s disease related dementia (AD/ADRD) to mitigate the risk of pressure injuries related to prolonged sitting. Pressure injury prevalence is disproportionately high in the aging AD/ADRD population due to ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. TeleLine: Plug-n-Play Inline Respiratory Remote Data Acquisition System

    SBC: OMNIBUS MEDICAL DEVICES, LLC            Topic: NINR

    Project Summary One in five Americans live in a rural community served by rural hospitals yet only 1% of ICU resources are available to these hospitals. When the level of care required by a patient exceeds the capabilities of the admitting hospital, the patient is transferred to a better-equipped tertiary hospital. Approximately 800,000 patients require mechanical ventilation every year in the Uni ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Structurally engineered furan fatty acids for the treatment of dyslipidemia and cardiovascular disease

    SBC: FURANICA, INC.            Topic: NHLBI

    1 Project Summary2 Cardiovascular risks in dyslipidemia patients are commonly controlled by lowering the LDL-C level using statins.3 However, a significant residual cardiovascular risk persists in patients with additional concurrent risk factors such4 as obesity, diabetes, insulin resistance, and elevated triglyceride-rich lipoproteins. Given the multifaceted5 underlying pathology of cardiovascula ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Microbial Synthesis of Therapeutic Bile Acids for Alzheimer's Disease

    SBC: Metselex, Incorporated            Topic: 105

    ABSTRACT This Phase STTR Phase II proposal aims to engineer and scale-up a synthetic metabolic pathway in a microbial host to produce UDCA and related compounds. Additionally, the UDCA produced from the engineered synthetic metabolic pathway will be used to synthesize derivatives for testing in our Alzheimer’s Disease cell and animal models. The proposed work has high intellectual merit for the ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. The DOVE Device to Prevent Opioid Overdose Deaths: An Armband That Senses Overdose and Automatically Injects Naloxone

    SBC: Altrumed LLC            Topic: NIDA

    ABSTRACT / PROJECT SUMMARY Despite the wide availability of the antidote naloxone, fatal opioid overdoses still occur at a rate of ~50-70,000 / year in the US. The problem is that naloxone requires a bystander to find and diagnose the overdose, find someone who has naloxone, and then properly administer it. Unfortunately, if this does not occur within 5 minutes, the patient will suffer from brain ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Optimizing the synthesis of[18F]FTMP for commercial distribution

    SBC: VELLUM BIOSCIENCES LLC            Topic: NIBIB

    Abstract The development of genetic medicines such as gene and cell therapies like Chimeric Antigen Receptor (CAR) T cells has necessitated new technologies that can monitor the biodistribution of these therapies in human patients. Imaging is particularly well suited to provide such quantitative measurements of a genetic medicine over time. Vellum Biosciences is a platform imaging company geared t ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Phosphatidylserine-blocking nanoparticles as improved anti-thrombotic with reduced bleeding risk

    SBC: MOLECULAR TARGETING TECHNOLOGIES, INC.            Topic: NHLBI

    We propose to develop a novel antithrombotic agent with improved efficacy and safety over standard of care via the following properties: 1) specific targeting to procoagulant surfaces, 2) high coagulant site binding and blocking capacity, 3) potent and specific effects of reducing clot size by selectively blocking only highly coagulant sites, 4) reducing bleeding risk compared with current antipla ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Development of a treatment for durable remission of HIV using transposon engineered CAR-T and NK cells

    SBC: MARPAM PHARMA LLC            Topic: NIAID

    Project Summary MarPam Pharma aims to develop a one-time treatment for achieving durable remission of human immunodeficiency virus (HIV), after which patients will no longer need to take antiretroviral therapy. Our treatment is an autologous HIV-specific chimeric antigen receptor (CAR) immune cell therapy that employs the CXCR5 chemokine receptor as a homing device to direct either anti-HIV T cell ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a Biomimetic Stentless Pulmonary Heart Valve for the Treatment of Pediatric Congenital Heart Disease

    SBC: NEOOLIFE, INC.            Topic: NHLBI

    PROJECT SUMMARY Congenital heart disease (CHD) is caused by defects in the heart structure that occur at birth and affect blood flow through the heart and the rest of the body. CHD affects around 10 out of 1,000 live-born children, 25% of which will need an intervention or surgery within their first year of life. Circa 1 million children and 1.4 million adults live with CHD in the US, and over 182 ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government